ArticleThe journal of allergy and clinical immunology. In practice2020
Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?
Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing-Recommendations on Best Practice (Update 2026).Contact dermatitis · 2026Guideline
- JAK inhibition may prevent drug hypersensitivity reactions.JCI insight · 2026Article
- Utility of IFN-γ Enzyme-Linked Immunospot as Adjunctive Diagnostic for Severe T Cell-Mediated Reactions to Cotrimoxazole in High HIV and Tuberculosis Settings.The journal of allergy and clinical immunology. In practice · 2025Article
- Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptoms.Current opinion in allergy and clinical immunology · 2025Review
- Updates in the pathogenesis of SJS/TEN.Allergology international : official journal of the Japanese Society of Allergology · 2025Review
- Overlapping of DRESS and Stevens-Johnson syndrome due to first-line antituberculosis drugs: a case report.Therapeutic advances in drug safety · 2025Article
- First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting.The journal of allergy and clinical immunology. In practice · 2024Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Immunological Mechanisms in Cutaneous Adverse Drug Reactions.Biomolecules & therapeutics · 2024Review
- Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB/HIV endemic setting.Frontiers in allergy · 2024Article
- Drug-induced hypersensitivity syndrome related to piperacillin-tazobactam: a case report and review of the literature.Frontiers in medicine · 2024Article
- Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions.Journal of clinical tuberculosis and other mycobacterial diseases · 2023Article
- Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Apalutamide: A Case Presentation.Cureus · 2023Article
- Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.The Journal of allergy and clinical immunology · 2023Review
- Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators.Biomedicines · 2023Review
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.The Journal of investigative dermatology · 2022Article
- Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics.Clinical reviews in allergy & immunology · 2022Review
- Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.The journal of allergy and clinical immunology. In practice · 2022Article
- The assessment of severe cutaneous adverse drug reactions.Australian prescriber · 2022Review
Corrections and comments
- Erratum issuedCorrection.2021
- Erratum issuedCorrigendum.2022
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Delayed immune-mediated adverse drug reactions (IM-ADRs) are defined as reactions occurring more than 6 hours after dosing. They include heterogeneous clinical phenotypes that are typically T-cell-mediated reactions with distinct mechanisms across a wide spectrum of severity from benign exanthems through to life-threatening cutaneous or organ-specific diseases. For mild reactions such as benign exanthem, considerations for delabeling are similar to immediate reactions and may include a graded or single-dose drug challenge with or without preceding skin or patch testing. Evaluation of challenging cases such as the patient who is on multiple drugs at the time a severe delayed IM-ADR occurs should prioritize clinical ascertainment of the most likely phenotype and implicated drug(s). Although not widely available and validated, procedures such as patch testing, delayed intradermal skin testing, and laboratory-based functional drug assays or genetic (human leukocyte antigen) testing may provide valuable information to further help risk stratify patients and identify the likely implicated and/or cross-reactive drug(s). The decision to use a drug challenge as a diagnostic or delabeling tool in a patient with a severe delayed IM-ADR should weigh the risk-benefit ratio, balancing the severity and priority for the treatment of the underlying, and the availability of alternative efficacious and safe treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.